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Abstract
Cerebrospinal fluid (CSF) 42 amino acid species of amyloid beta (Ab42) and tau levels are strongly correlated with the
presence of Alzheimer’s disease (AD) neuropathology including amyloid plaques and neurodegeneration and have been
successfully used as endophenotypes for genetic studies of AD. Additional CSF analytes may also serve as useful
endophenotypes that capture other aspects of AD pathophysiology. Here we have conducted a genome-wide association
study of CSF levels of 59 AD-related analytes. All analytes were measured using the Rules Based Medicine Human
DiscoveryMAP Panel, which includes analytes relevant to several disease-related processes. Data from two independently
collected and measured datasets, the Knight Alzheimer’s Disease Research Center (ADRC) and Alzheimer’s Disease
Neuroimaging Initiative (ADNI), were analyzed separately, and combined results were obtained using meta-analysis. We
identified genetic associations with CSF levels of 5 proteins (Angiotensin-converting enzyme (ACE), Chemokine (C-C motif)
ligand 2 (CCL2), Chemokine (C-C motif) ligand 4 (CCL4), Interleukin 6 receptor (IL6R) and Matrix metalloproteinase-3
(MMP3)) with study-wide significant p-values (p,1.46610210) and significant, consistent evidence for association in both
the Knight ADRC and the ADNI samples. These proteins are involved in amyloid processing and pro-inflammatory signaling.
SNPs associated with ACE, IL6R and MMP3 protein levels are located within the coding regions of the corresponding
structural gene. The SNPs associated with CSF levels of CCL4 and CCL2 are located in known chemokine binding proteins.
The genetic associations reported here are novel and suggest mechanisms for genetic control of CSF and plasma levels of
these disease-related proteins. Significant SNPs in ACE and MMP3 also showed association with AD risk. Our findings
suggest that these proteins/pathways may be valuable therapeutic targets for AD. Robust associations in cognitively normal
individuals suggest that these SNPs also influence regulation of these proteins more generally and may therefore be
relevant to other diseases.
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Introduction
Cerebrospinal fluid (CSF) contains promising biomarkers for
neurological and psychiatric diseases such as Alzheimer’s disease
(AD), schizophrenia, and Parkinson’s disease [1–4]. The brain
directly and rapidly influences the composition of CSF, and as
such, CSF analytes may provide insights into neurological and
psychiatric disease pathways that may not be identifiable using
blood or other biological fluids.
The use of endophenotypes in genome-wide association studies
(GWAS) has provided novel insights into pathways and proteins
that are associated with AD onset and progression [5,6]. We have
demonstrated the utility of CSF amyloid-beta (Ab), apolipoprotein
E (ApoE) and tau levels as endophenotypes for genetic studies of
AD [7–16]. In our most recent work we used nearly 1,300 samples
to conduct a GWAS with CSF tau levels [9]. In that study,
Cruchaga et al. identified three genome-wide significant loci,
including rs9877502, which also showed a consistent association
with AD risk, tangle pathology, and global cognitive decline in
independent datasets. The success of these and other similar efforts
has led to broader efforts to develop and leverage datasets of this
type [17–27].
While amyloid plaques and neurofibrillary tangles are the
primary pathological features of AD, genetic, clinical, and animal
studies demonstrate that endocytosis, cholesterol metabolism, and
inflammatory and immune responses also play an important roles
in AD pathogenesis [28]. To further leverage the advantages of
the endophenotype based approach, we have sought to use
analytes related to these other aspects of AD pathology. For this
work we have obtained data from the Rules Based Medicine, Inc.
(RBM) (Austin, TX) Human DiscoveryMAP Panel. This panel
includes over 175 analytes selected from the constellation of
known cytokines, chemokines, metabolic markers, hormones,
growth factors, tissue remodeling proteins, angiogenesis markers,
acute phase reactants, cancer markers, kidney damage markers,
and central nervous system biomarkers. Analytes were quantita-
tively measured in CSF samples from 574 samples (including both
cognitively normal and demented individuals) from two indepen-
dent datasets to identify novel phenotypes that may contribute to
the pathogenesis of AD. After careful quality control and
evaluation of the literature we selected 59 AD-related analytes
for analysis in genome-wide association studies. We identified
genome-wide significant associations between putatively func-
tional SNPs and five phenotypes (Angiotensin-converting enzyme
(ACE), Chemokine (C-C motif) ligand 2 (CCL2), Chemokine (C-
C motif) ligand 4 (CCL4), Interleukin 6 receptor (IL6R) and
Matrix metalloproteinase-3 (MMP3)). The genetic basis of
variance in these important disease-related analytes may provide
insights into the mechanisms contributing to AD and other
human diseases.
Results
From the combined GWAS on 59 phenotypes with connec-
tions to AD in our literature search (table 1) and with 5.8M
SNPs (table 1), we identified 335 SNPs associated with five CSF
phenotypes where p,1.47610210 (Bonferroni correction for
342 million tests) and other filtering criteria (see Methods:
Statistical Analysis) were met (Table S1). At least one study-wide
significant marker was directly genotyped (not imputed) for each
locus that showed association. While there were other genome-
wide significant associations with several of the other 54
phenotypes, these signals did not meet the additional filtering
criteria. At least one SNP met the study-wide significance level
(1.46610210) for each of the five phenotypes discussed in detail
below (Table 2). All associations were robust to adjustment for
APOE e4 genotype and CDR. In addition, all associations were
qualitatively stable in clinical case/control strata as well as in
strata approximating presence or absence of amyloid deposition
based on CSF Ab42 levels (Table 3). The most significant
marker for each phenotype, all SNPs in the associated regions
with putative function, and markers with previous records in the
National Human Genome Research Institute (NHGRI) catalog
of published genome-wide association studies (downloaded
November 19th, 2013; http://www.genome.gov/gwastudies/)
are listed in Table 2. P-values of all SNPs in the region
surrounding each significant association are plotted in Figure 1.
Manhattan plots for the five phenotypes can be found in
supplementary figures S1-S5. Detailed descriptions of each gene
can be found in Text S1.
Effects of age and gender
We observed a significant association between CSF MMP3 and
CCL2 and gender, where both analytes were lower in females
relative to males in cognitively normal samples from both ADNI
and the Knight ADRC. We also observed significantly increased
MMP3 and CCL2 levels with increasing age in cognitively normal
samples from both ADNI and the Knight ADRC. We failed to
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detect consistent association in both the ADNI and Knight ADRC
samples with plasma levels of these analytes and age or gender.
Full results including slopes of the regression models can be found
in table S2 (CSF results) and table S3 (plasma results).
Association results
Angiotensin-converting enzyme (ACE). We identified sev-
en SNPs significantly associated with ACE levels in CSF
(Figure 1A). The minor allele of rs4968782 was associated with
higher ACE CSF protein levels (p = 3.94610212) and explains
11% of the variance in CSF ACE levels. The signal was consistent
in cases/controls and in CSF Ab42 strata defining presence/
absence of Aß pathology and was also observed between this SNP
and plasma ACE levels (p = 7.93610216). A synonymous substi-
tution in the ACE gene, rs4343 (rs4968782/rs4343: r2 = 0.93;
D9=1.0), was also associated with ACE levels in CSF and plasma
(p = 3.7161028; p = 1.1061028, respectively). CSF and plasma
levels of ACE showed a significant and moderate correlation
(Pearson’s correlation coefficient = 0.28, p = 4.8661026). Another
synonymous substitution, rs4316 is also in high LD with these
markers and shows significant association with CSF and plasma
levels of ACE (see table 3). Both rs4343 and rs4316 are predicted
as ‘‘likely to affect binding transcription factors’’ by RegulomeDB.
None of these SNPs remained significant after conditioning upon
the others. Rs4343 also appears in the NHGRI GWAS catalog
associated with increased ACE activity levels in serum [29].
Association with AD status was observed (all four SNPs p,0.0075)
in 17,008 AD cases and 37,154 controls from the International
Genomics of Alzheimer’s Project (IGAP) as described by Lambert
et al and accessible at http://www.pasteur-lille.fr/en/recherche/
u744/igap/igap_download.php [30]. For each of the four ACE
SNPs, rs4968782, rs4459609, rs4316 and rs4343, the same allele
was associated with increased ACE levels and decreased risk for
AD (table 3).
Chemokine (C-C motif) ligand 2 (CCL2) also known as
monocyte chemotactic protein 1. We identified one SNP,
rs2228467, which results in a non-synonymous change (V41A) in
the chemokine binding protein-2 (CCBP2) that is associated with
increased CCL2 protein levels (CSF p= 3.71610218). This marker
accounts for 13% of the variance in CSF CCL2 levels. Other
SNPs in this region with moderate linkage disequilibrium (LD) also
showed strong, but not study-wide significant, associations
(Figure 1B). The association of rs2228467 with CSF levels of
CCL2 remained significant in cases/controls and in CSF Ab42
strata defining presence/absence of Ab pathology and was
nominally associated with CCL2 levels in plasma (table 3). CSF
and plasma CCL2 levels were significantly correlated (Pearson’s
correlation coefficient = 0.23, p = 1.9361024). Both SIFT and
PolyPhen2 predicted the rs2228467 V41A change to be damaging.
The IGAP analysis failed to detect association between rs2228467
and risk for AD (table 3) [30]. We failed to detect association
between CSF CCL2 levels and AD status (p = 0.90). This SNP was
not associated with other phenotypes in the NHGRI GWAS
catalog.
Chemokine (C-C motif) ligand 4 (CCL4) also known as
macrophage inflammatory protein 1 beta. We identified 66
polymorphisms associated with CCL4 levels in CSF. This is a trans
effect, all associated SNPs are located within a 187 kb region of
chromosome 3 surrounding the Chemokine (C-C Motif) Receptor-
Like 2 (CCRL2) gene (figure 1C). The most significant association
was observed with rs6808835 (p= 1.59610213). A non-synony-
mous SNP in the CCRL2 gene, rs6441977 (rs6808835/rs6441977:
r2 = 0.93; D9=1.0), results in a V180M substitution and shows
significant association with CSF CCL4 levels in the combined
sample (p = 7.66610211) with CCL4 levels decreasing with each
copy of the minor allele. This SNP explains 10% of the variance in
CSF CCL4 levels. Several significant, intergenic markers in this
same region are predicted as ‘‘likely to affect transcription factor
binding and gene expression’’ (rs6762266, rs11575821,
rs11574428) and ‘‘likely to affect transcription factor binding’’
(rs113263161, rs3092960) using RegulomeDB. None of these
SNPs remained significant after conditioning upon the others. In
addition to the association in the total dataset, this SNP shows
consistent association in cases/controls, in CSF Ab42 strata
defining presence/absence of Ab pathology and with CCL4 levels
in plasma (table 3). CSF and plasma levels of CCL4 were
significantly correlated (Pearson’s correlation coefficient = 0.37,
p = 6.59610210). SIFT and PolyPhen 2 predicted the amino acid
change to be benign. No SNPs associated with CCL4 showed
significant association with AD in the IGAP analysis (table 3) and
no significant SNPs were associated with other phenotypes in the
NHGRI GWAS catalog.
Interleukin 6 receptor (IL6R). We identified 176 SNPs
significantly associated with soluble IL6R (sIL6R) levels in CSF.
These significant SNPs were located in the region of chromosome
1 surrounding the TDRD12, SHE, and IL6R genes (figure 1D).
The most significant association was with rs61812598
(p = 5.9610262). Two non-synonymous SNPs were also associated
with increased sIL6R protein levels in both CSF and plasma:
rs2228145 (gene = IL6R, D358A, CSF p=2.70610262, plasma
p= 4.64610267) and rs3811448 (gene=TDRD10, V215I, CSF
p= 3.36610215, plasma p= 7.91610212). CSF and plasma levels
of sIL6R showed a significant correlation (Pearson’s correlation
coefficient = 0.49, p = 2.20610216). In addition, rs2228145 exhib-
its nearly perfect LD with rs61812598 (r2 = 0.99; D9=1.0).
Rs3811448 has a high D9 with both rs2228145 (D9=0.96) and
rs61812598 (D9=0.96) but its r2 with these SNPs is low (r2 = 0.15
with both SNPs). Another significant SNP in this region,
rs4129267, has nearly complete LD with both rs61812598 and
rs2228145 (D9.0.99, r2.0.99 in both cases), and is predicted by
RegulomeDB as ‘‘likely to affect transcription factor binding.’’
Tests conditioning on any of these SNPs results in no significant
associations in this region. Associations with both rs2228145 and
rs61812598 (essentially the same test as they exhibit nearly perfect
LD) remained genome-wide significant when conditioning upon
Author Summary
The use of quantitative endophenotypes from cerebrospi-
nal fluid has led to the identification of several genetic
variants that alter risk or rate of progression of Alzheimer’s
disease. Here we have analyzed the levels of 58 disease-
related proteins in the cerebrospinal fluid for association
with millions of variants across the human genome. We
have identified significant, replicable associations with 5
analytes, Angiotensin-converting enzyme, Chemokine (C-C
motif) ligand 2, Chemokine (C-C motif) ligand 4, Interleukin
6 receptor and Matrix metalloproteinase-3. Our results
suggest that these variants play a regulatory role in the
respective protein levels and are relevant to the inflam-
matory and amyloid processing pathways. Variants in
associated with ACE and those associated with MMP3
levels also show association with risk for Alzheimer’s
disease in the expected directions. These associations are
consistent in cerebrospinal fluid and plasma and in
samples with only cognitively normal individuals suggest-
ing that they are relevant in the regulation of these protein
levels beyond the context of Alzheimer’s disease.
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Table 1. Analyte names.
Human Discovery MAP v1.0 Name Official Protein Name Official Gene Name
Adiponectin Adiponectin (ADIPO) Adiponectin (ADIPOQ)
Alpha-1 antitrypsin (AAT) Alpha-1-antitrypsin (A1AT) Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 1 (SERPINA1)
Alpha-1-microglobulin (A1M) Alpha-1-microglobulin (AMBP) Alpha-1-microglobulin/bikunin precursor (AMBP)
Alpha-2-Macroglobulin (A2M) Alpha-2-macroglobulin (A2M) Alpha-2-macroglobulin (A2M)
Angiopoietin-2 (ANG-2) Angiopoietin-2 (ANG-2) Angiopoietin 2 (ANGPT2)
Angiotensin-converting enzyme (ACE) Angiotensin I-converting enzyme (ACE) Angiotensin I-converting enzyme (ACE)
Apolipoprotein A-I (Apo A-I) Apolipoprotein A-I (Apo A-I) Apolipoprotein A-I (APOA1)
Apolipoprotein D (Apo D) Apolipoprotein D (Apo D) Apolipoprotein D (APOD)
Apolipoprotein E (Apo E) Apolipoprotein E (Apo E) Apolipoprotein E (APOE)
Beta-2-microglobulin (B2M) Beta-2-microglobulin (B2MG) Beta-2-microglobulin (B2M)
C-reactive protein (CRP) C-reactive protein (CRP) C-reactive protein (CRP)
CD 40 antigen (CD40) CD40 protein (CD40) CD40 molecule (CD40)
Chemokine CC-4 (HCC-4) C-C motif chemokine 16 (CCL16) Chemokine (C-C motif) ligand 16 (CCL16)
Chromogranin-A (CgA) Chromogranin-A (CgA) Chromogranin A (CHGA)
Clusterin (CLU) Clusterin (CLU) Clusterin (CLU)
Complement C3 (C3) Complement component 3 (C3) Complement component 3 (C3)
Cortisol Hydrocortisone Brain-derived neurotrophic factor (BDNF)
Cystatin-C Cystatin-C (CYTC) Cystatin C (CST3)
Fas ligand (FasL) Tumor necrosis factor ligand superfamily
member 6 (TNFL6)
Fas ligand (TNF superfamily, member 6) (FASLG)
Fatty Acid-Binding Protein, heart (H-FABP) Fatty acid-binding protein, heart (H-FABP) Fatty acid binding protein 3, muscle and heart (FABP3)
Ferritin (FRTN) Ferritin heavy chain (FRIH)/light chain (FRIL) Ferritin, heavy polypeptide 1 (FTH1)/light polypeptide (FTL)
Fibrinogen Fibrinogen alpha chain (FIBA)/beta chain (FIBB)/
gamma chain (FIBG)
Fibrinogen alpha chain (FGA)/beta chain (FGB)/gamma chain
(FGG)
Follicle Stimulating Hormone (FSH) Glycoprotein hormones alpha chain (GLHA)/
Follitropin subunit beta (FSHG)
Glycoprotein hormones, alpha polypeptide (CGA)/follicle
stimulating hormone, beta polypeptide (FSHG)
Hepatocyte growth factor (HGF) Hepatocyte growth factor (HGF) Hepatocyte growth factor (HGF)
Insulin like growth factor binding protein 2
(IGFBP-2)
Insulin-like growth factor-binding protein 2 (IBP2) Insulin-like growth factor binding protein 2 (IGFBP2)
Intercellular adhesion molecule 1 (ICAM-1) Intercellular adhesion molecule 1 (ICAM1) Intercellular adhesion molecule 1 (ICAM1)
Interferon gamma Induced Protein 10
(IP-10; CXCL10)
C-X-C motif chemokine 10 (CXL10) Chemokine (C-X-C motif) ligand 10 (CXCL10)
Interleukin 3 (IL-3) Interleukin 3 (IL3) Interleukin 3 (IL3)
Interleukin-16 (IL-16) Pro-interleukin-16 (IL16) Interleukin 16 (IL16)
Interleukin-6 receptor (IL-6R) Interleukin-6 receptor subunit alpha (IL6RA) Interleukin 6 receptor (IL6R)
Interleukin-8 (IL-8) Interleukin-8 (IL8) Interleukin 8 (IL8)
Lectin-like oxidized low-density lipoprotein
receptor 1 (LOX-1)
Oxidized low-density lipoprotein receptor 1 (OLR1) Oxidized low density lipoprotein (lectin-like) receptor 1 (OLR1)
Leptin Leptin (LEP) Leptin (LEP)
Macrophage Inflammatory Protein-1
beta (MIP-1 beta)
Chemokine (C-C motif) ligand 4 (CCL4) Chemokine (C-C motif) ligand 4 (CCL4)
Macrophage migration inhibitory factor (MIF) Macrophage migration inhibitory factor (MIF) Macrophage migration inhibitory factor
(glycosylation-inhibiting factor) (MIF)
Matrix metalloproteinase-2 (MMP-2) 72 kDa type IV collagenase (MMP2) Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase,
72 kDa type IV collagenase) (MMP2)
Matrix Metalloproteinase-3 (MMP-3) Matrix metalloproteinase 3 (MMP3) Matrix metallopeptidase 3 (MMP3)
Monocyte Chemotactic Protein 1 (MCP-1) Chemokine (C-C motif) ligand 2 (CCL2) Chemokine (C-C motif) ligand 2 (CCL2)
Myoglobin Myoglobin (MYG) Myoglobin (MG)
N-terminal prohormone of brain natriuretic
peptide (NT proBNP)
Natriuretic peptides B (ANFB) Natriuretic peptide B (NPPB)
Osteopontin (OPN) Osteopontin (OPN) Secreted phosphoprotein 1 (SPP1)
Pancreatic polypeptide (PPP) Pancreatic prohormone (PAHO) Pancreatic polypeptide (PPY)
Genetics Associations with CSF Protein Levels of AD-Related Analytes
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rs3811448. Rs2228145 accounts for about 40% of variance in
CSF sIL6R levels. Neither amino acid change is predicted to affect
its respective protein’s function by SIFT or Polyphen 2. The IGAP
analysis failed to detect association between the markers associated
with sIL6R and AD risk (table 3) [30]. We found significant SNPs
in our analyses that have been previously reported to be associated
with asthma [31], C-reactive protein levels (rs4129267) [32], and
coronary heart disease (rs2229238) [33] in the NHGRI GWAS
catalog.
Matrix metalloproteinase-3 (MMP3). Eighty-five SNPs
were significantly associated with MMP3 levels (figure 1E). The
most significant association was observed with rs573521
(p = 2.39610244). A non-synonymous mutation in MMP3,
rs679620 (K45E), shows high LD with rs573521 (r2 = 0.99;
D9=1.0). Neither of these two SNPs remained significant after
conditioning upon the other. Rs679620 was also significantly
associated with MMP3 levels in CSF (p=4.93610244) with
MMP3 levels increasing with each copy of the minor allele. This
SNP accounts for about 30% of the variance in CSF MMP3 levels.
Association of this marker is consistent in cases/controls and in CSF
Ab42 strata defining presence/absence of Ab pathology and was also
observed nominally with plasma MMP3 levels (table 3). CSF and
plasma MMP3 levels were moderately and significantly correlated
(Pearson’s correlation coefficient= 0.33, p=2.0661025). SIFT and
PolyPhen 2 predicted the rs679620 K45E amino acid change to be
benign. Rs948399 also showed significant association and was
predicted by RegulomeDB as ‘‘likely to affect transcription factor
binding.’’ Three SNPs, rs573521, rs645419 and rs679620 showed
nominal significance in the IGAP AD association analysis (table 3).
From the NHGRI GWAS catalog, five SNPs previously reported to
be associated with MMP1 levels in plasma in a recent genome-wide
association study (rs7926920, rs11225434, rs495366, rs603050, and
rs650108) [34] are also significantly associated with MMP3 levels in
CSF in our data. MMP3 and MMP1 are located in the same region
on chromosome 11 and show strong correlation in their pattern of
expression [35,36] suggesting that there may be coordinated
regulation of these two genes. These SNPs are located in the
37 kb region between MMP3 and MMP1 and show high LD
(D9,1) with rs573521 and rs679620.
Multivariate analysis of top SNPs. We used Multiphen, to
perform a multivariate test of the linear combination of
phenotypes most associated with the genotypes at each of our
top SNPs [37]. At least one marker from each of the loci in our top
hits showed genome-wide significance in the joint models
(Table 4). Several SNPs showed strong association with sIL6R
and prolactin (PRL). Rs2228467, which showed primary associ-
ation with CCL2, also showed association with glutamic-
oxaloacetic transaminase 1 (GOT1). Full results including p-values
and metaanalysis of each of the top SNPs with each phenotype are
provided in Table S4.
Discussion
We have identified loci significantly associated with levels of five
AD-related CSF analytes. Our findings include cis effects (defined
as SNPs within 5 kb on either side of the transcribed gene) for
ACE, sIL6R and MMP3 levels and trans effects for CCL2 and
CCL4 levels. For each of the loci except ACE, a non-synonymous
SNP is among the most strongly associated variants. SNPs in all
five loci were associated with each of the analytes even after a
highly conservative multiple test correction (alpha = 1.46610210).
All results are consistent when analyses are stratified by clinical
status and when stratified by CSF Ab42 levels that are indicative of
AD pathology, suggesting that these results are relevant in normal
Table 1. Cont.
Human Discovery MAP v1.0 Name Official Protein Name Official Gene Name
Plasminogen Activator Inhibitor 1 (PAI-1) Plasminogen activator inhibitor 1 (PAI1) Serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1 (SERPINE1)
Prolactin (PRL) Prolactin (PRL) Prolactin (PRL)
S100 calcium-binding protein B (S100-B) Protein S100-B (S100B) S100 calcium binding protein B (S100B)
Secretory Immunoglobulin A (IgA) Immunoglobulin A (IgA) CD79a molecule, immunoglobulin-associated alpha (CD79A)
Serum Amyloid P-Component (SAP) Serum amyloid P-component (SAMP) Amyloid P component, serum (APCS)
Serum glutamic oxaloacetic
transaminase (SGOT)
Aspartate transaminase (AST) glutamic-oxaloacetic transaminase 1, soluble (GOT1)
Sex hormone-binding globulin (SHBG) Sex hormone-binding globulin (SHBG) Sex hormone-binding globulin (SHBG)
Sortilin-1 Sortilin (SORT) Sortilin 1 (SORT1)
Stem Cell Factor (SCF) Kit ligand (SCF) KIT ligand (KITLG)
T-Cell-Specific Protein RANTES (RANTES; CCL5) C-C motif chemokine 5 (CCL5) chemokine (C-C motif) ligand 5 (CCL5)
Tissue inhibitor of metalloproteinases
1 (TIMP-1)
Metalloproteinase inhibitor 1 (TIMP1) TIMP metallopeptidase inhibitor 1 (TIMP1)
Transforming growth factor alpha (TGF-alpha) Transforming growth factor alpha (TGFA) Transforming growth factor, alpha (TGFA)
Tumor necrosis factor receptor 2 (TNFR2) Tumor necrosis factor receptor superfamily
member 1B (TNR1B)
Tumor necrosis factor receptor superfamily, member 1B
(TNFRSF1B)
Tumor necrosis factor-related apoptosis-
inducing ligand receptor 3 (TRAIL-R3)
Tumor necrosis factor receptor superfamily
member 10C (TR10C)
Tumor necrosis factor receptor superfamily, member 10c,
decoy without an intracellular domain (TNFRSF10C)
Vascular cell adhesion molecule-1 (VCAM-1) Vascular cell adhesion protein 1 (VCAM1) Vascular cell adhesion molecule 1 (VCAM1)
Vascular endothelial growth factor (VEGF) Vascular endothelial growth factor A (VEGFA) Vascular endothelial growth factor A (VEGFA)
von Willebrand factor (vWF) von Willebrand factor (vWF) von Willebrand factor (vWF)
The name of each ‘‘AD-related’’ analyte in the Human Discovery MAP panel, official protein name and official structural gene name are presented.
doi:10.1371/journal.pgen.1004758.t001
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conditions, not just in the context of AD. In addition, all of the
associated SNPs showed association with their respective plasma
analytes, further supporting the robustness of the genetic
associations. The ACE, MMP3 and CCL2 proteins have been
previously described to have an impact on amyloid beta
processing. The remaining proteins are involved in the pro-
inflammatory response. The results of our Multiphen analysis did
not provide strong evidence that these SNPs regulate expression of
multiple traits in similar pathways.
Angiotensin-converting enzyme (ACE)
Angiotensin converting enzyme (ACE) is encoded by the ACE
gene (17q23.3) and has been previously implicated in AD
pathogenesis. In vitro, ACE inhibits Ab aggregation in an
activity-dependent manner by slowing the rate of fibril formation
[38–40]. ACE may inhibit Ab aggregation by converting the
highly amyloidogenic Ab42 peptide into the more stable Ab40
peptide [41]. In vivo, inhibition of ACE activity in an AD mouse
model promotes Ab42 deposition in the hippocampus [41].
Studies in mouse and human brain homogenate demonstrate that
ACE causes Ab degradation in a two-step process. First, ACE
cleaves Ab42 into Ab40 and then Ab40 undergoes degradation
[41].
ACE activity is elevated in the CSF of AD patients [42].
Neuroblastoma cells exposed to synthetic Ab42 oligomers, but not
monomeric Ab42, produce elevated ACE protein levels and ACE
activity, suggesting that Ab aggregates may stimulate the up-
regulation of ACE in AD brains as a mechanism of combatting the
accumulation of these protein aggregates.
Our findings suggest that SNPs within the ACE locus alter CSF
and plasma ACE levels. Several SNPs in the ACE gene region
have significant associations with increased levels of ACE.
Figure 1. Plots for the region surrounding the genome-wide significant locus for each phenotype. A) region of rs4968782 (ACE), B)
region of rs2228467 (CCL2), C) region of rs6808835 (CCL4), D) region of rs61812598 (IL6R), E) region of rs573521 (MMP3). The top SNP for each region is
shown in purple. The correlations (r2) of each of the surrounding SNPs to the top SNP are shown in the indicated colors. Recombination rate is shown
in blue. SNP annotation is as follows: circle = framestop, square-splice, diamond=nonsynonymous, triangle = coding, inverted triangle =UTR,
X = conserved transcription factor binding, square with X =MCS44Placental, star = no annotation, circle with crosshairs = none.
doi:10.1371/journal.pgen.1004758.g001
Table 4. Multiphen analysis.
SNP CHR BP Primary Knight ADRC ADNI Analytes
rs4845622 chr1 154411419 IL6R 3.35E-54 8.56E-71 PRL
rs61812598 chr1 154420087 IL6R 4.12E-56 2.38E-81 PRL
rs4129267 chr1 154426264 IL6R 9.56E-55 7.41E-82 PRL
rs2228145 chr1 154426970 IL6R 9.56E-55 7.41E-82 PRL
rs2229238 chr1 154437896 IL6R 1.34E-10 1.86E-10 N/A
rs3811448 chr1 154516578 IL6R 3.17E-12 5.37E-11 N/A
rs2228467 chr3 42906116 CCL2 4.72E-09 4.19E-16 GOT1
rs3092960 chr3 46400062 CCL4 2.91E-07 8.33E-08 N/A
rs11575821 chr3 46422355 CCL4 3.47E-07 1.02E-09 N/A
rs113263161 chr3 46425718 CCL4 2.24E-07 7.70E-08 N/A
rs11574428 chr3 46446721 CCL4 9.59E-06 2.27E-09 N/A
rs6808835 chr3 46449864 CCL4 1.65E-05 2.67E-11 N/A
rs6441977 chr3 46450072 CCL4 1.04E-05 3.10E-08 N/A
rs6762266 chr3 46452863 CCL4 2.15E-05 2.67E-11 N/A
rs603050 chr11 102680229 MMP3 5.36E-07 2.36E-10 N/A
rs11225434 chr11 102691482 MMP3 3.64E-27 1.82E-42 N/A
rs495366 chr11 102695108 MMP3 8.37E-10 9.67E-13 N/A
rs7926920 chr11 102698724 MMP3 6.92E-29 1.67E-46 N/A
rs650108 chr11 102708787 MMP3 5.06E-09 3.40E-12 N/A
rs679620 chr11 102713620 MMP3 8.58E-31 1.14E-48 N/A
rs645419 chr11 102716321 MMP3 8.58E-31 8.54E-49 N/A
rs573521 chr11 102716980 MMP3 8.58E-31 3.46E-48 N/A
rs948399 chr11 102771140 MMP3 4.28E-11 9.87E-10 N/A
rs4968782 chr17 61548476 ACE 3.93E-10 7.09E-12 N/A
rs4459609 chr17 61548948 ACE 3.19E-10 3.31E-12 N/A
rs4316 chr17 61562309 ACE 5.04E-06 3.91E-17 N/A
rs4343 chr17 61566031 ACE 3.98E-06 4.46E-19 N/A
For each SNP the rs number (SNP, the chromosome (CHR), base pair position (BP) primary associated analyte (Primary), p-value from joint phenotype testing in the
Knight ADRC and ADNI samples, and the additional associated phenotypes (Secondary) after Bonferroni correction for 28 SNPs (alpha = 0.0018) is shown.
doi:10.1371/journal.pgen.1004758.t004
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Conditional analyses suggest a single signal in this region is
responsible for the association. While we are unable to determine
the specific functional allele in this region, rs4343 and rs4316 are
in nearly perfect LD with each other (D9=0.99, r2 = 0.91) and
both are inferred to have regulatory function (table 3). Rs4316 has
not been studied in AD or reported to be associated with other
phenotypes to date. Rs4343 is a widely studied marker in ACE,
and we found a significant association of this SNP with increased
CSF ACE levels. The minor allele ‘‘G’’ of rs4343 has been
previously reported to be significantly associated with increased
plasma ACE activity levels and plasma ACE protein levels [21,29].
Our observation of increased CSF ACE levels with the G allele of
rs4343 is consistent with these reports.
In relation to AD, the findings with rs4343 have been varied
with some studies suggesting association with CSF Ab42 levels and
AD risk while others do not [14,43–49]. Recent data from 1269
samples with CSF and genetic data failed to detect association
between CSF Ab42, Tau or pTau181 levels and these SNPs in
ACE (table 3) [9]. Results from the recent International Genomics
of Alzheimer’s Project provide evidence of association between the
SNPs in ACE we report to be associated with higher CSF ACE
levels and reduced risk for AD [30]. In addition, recent work using
600 samples with CSF ACE measurements found a significant
increase in ACE levels with increasing ptau/Ab42 ratio (which
was used as a predictor of AD status) [50], further reinforcing the
relationship between ACE levels and AD status.
Our results demonstrate in human subjects that SNPs in the
ACE gene are associated with elevated CSF and plasma ACE
protein levels and that these SNPs are also associated with reduced
AD risk. Taken with in vitro and in vivo studies that demonstrate
that ACE cleaves and clears Ab in an activity-dependent manner,
these findings suggest that individuals carrying polymorphisms
that increase ACE protein, and possibly ACE activity, may be
better able to clear accumulating Ab aggregates and are thus at
reduced risk for developing AD.
Matrix metalloproteinase-3 (MMP3)
Matrix metalloproteinase 3 (encoded by MMP3; located on
11q22.3) is hypothesized to contribute to endogenous, physiologic
clearance of amyloid plaques. MMP3 is expressed in neurons,
astrocytes, microglia and vascular cells [51]. MMP3 is preferen-
tially localized in senile plaques in the parietal cortex of AD brains,
while hippocampal plaques are relatively spared of MMP3 [52].
Ab treatment causes upregulation of MMP3 expression in primary
astrocyte cultures and in mixed hippocampal cultures [53]. MMP3
also degrades extracellular Ab [54]. The closely related MMP2
and MMP9 proteins have been well studied in the context of AD
pathogenesis. Astrocytes that surround plaques in AD mouse
brains show enhanced MMP2 and MMP9 expression [55].
Conditioned astrocyte media is sufficient to reduce synthetic Ab
levels, which is abolished with treatment of inhibitors specific to
MMP2 and MMP9 [55]. MMP9 can degrade fibrillar Ab in vitro
and plaques in hippocampal slice cultures [52,56,57]. In an AD
mouse model, knocking out MMP2 and MMP9 results in
increased steady-state Ab [55]. Thus, MMP proteins may
contribute to Ab clearance by promoting Ab catabolism.
Supporting the relationship of MMP3 with Alzheimer’s disease,
CSF MMP3 levels are increased in individuals with a ptau181/
Ab42 ratio indicative of AD [50]. In a previous study, we failed to
detect an association between significant SNPs in this study and
CSF Ab42, Tau or pTau181 levels (table 3) [9]. Studies testing the
association of MMP3 SNPs and haplotypes and risk for AD have
produced mixed results [58–60]. There appears to be two tiers of
association in this locus, one group of SNPs with p-values less than
1E-38, which includes the non-synonymous SNP rs679620, and
another which p-values between 1E-08 and 1E-12, including
several variants with inferred regulatory function. Conditional
analyses of our data in this region indicate that the more strongly
associated group of variants tags a single association signal and
that no independent associations are detected in this region. While
we cannot definitively identify the causal variant, rs679620, a non-
synonymous SNP in the MMP3 region, was significantly
associated with increased CSF MMP3 levels. This suggests a
possible protective effect of this variant with respect to AD. We
found that rs573521, rs645419 and rs679620 are associated with
increased CSF MMP3 levels in this study and with reduced risk of
AD in the IGAP study. These associations provide additional
support for the role of MMP3 in AD pathology. In addition, the
identification of SNPs in the intergenic region between MMP3
and MMP1 that are associated with both MMP3 and MMP1
levels suggest a common regulatory locus or close functional
relationship between these members of the MMP gene family.
The identification of SNPs near MMP3 that are associated with
increased CSF MMP3 protein levels and reduced AD risk supports
the protective role of MMP3 in clearing Ab from human brains.
Chemokine (C-C motif) ligand 2 (CCL2)
CCL2, also called monocyte chemotactic protein-1 or MCP-1,
is encoded by the CCL2 gene, located on chromosome 17q11.2-
q12. It is a chemokine that is involved in immunoregulatory and
pro-inflammatory processes. Amyloid plaques in AD brains are
surrounded by activated immune cells that produce CCL2 among
other chemokines [61]. In the absence of CCL2, amyloid
pathology is accelerated in an AD mouse model, illustrating its
important role in amyloid plaque clearance and pointing to a
potentially reparative role in AD [62]. However, overexpression of
CCL2 in an AD mouse model resulted in marked accumulation of
reactive microglia and enhanced diffuse plaque accumulation,
suggesting a role in Ab aggregation [63]. In vitro work suggests
that inhibition of CCL2 synthesis, reduces Ab25–35- and Ab1–42-
induced toxicity in primary neuronal cultures [64]. Interestingly,
treatment of primary astrocyte cultures with synthetic Ab42 causes
astrocytes to increase CCL2 synthesis and release [64] and
astrocyte migration in response to CCL2 is reduced in the
presence of Ab42 [65]. Thus, Ab42 in AD brains may stimulate
astrocyte-mediated CCL2 release and result in increased neuronal
susceptibility to Ab42 toxicity. The immune system involves a
delicate and perfectly coordinated balance to function well; so, it is
conceivable that CCL2 could play reparative and deleterious roles
in AD pathogenesis.
A 2006 study evaluated CCL2 levels in serum samples from 48
individuals with Mild Cognitive Impairment (MCI), 94 AD
patients and 24 age-matched controls [66]. Significantly increased
plasma CCL2 levels were found in MCI and mild AD, but not in
severe AD patients, as compared with controls. It has also been
reported that increased CSF CCL2 levels at baseline in patients
with prodromal AD correlated with a faster cognitive decline
during the study’s follow-up period [67]. The largest study to date
examined 600 samples with CSF CCL2 measurements and
observed a significant increase in CCL2 protein levels with
ptau/Ab42 ratio indicative of AD [50]. As is the case with most
pro-inflammatory cytokines and cytokine receptors, the levels
increase in AD cases.
Rs2228467, located within the CCBP2 gene, is significantly
associated with increased CSF CCL2 protein levels. The CCBP2
gene encodes the chemokine-binding protein 2 and demonstrates a
high affinity for binding to CCL2 [68]. Conditional analyses
suggest that this marker accounts for the entirety of the association
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signal in this region. Previous studies suggest that chemokine
receptors can demonstrate high affinity binding to chemotactic
proteins [68]; however, how polymorphisms in one chemokine
affect expression and function of associated chemokines is poorly
understood. PolyPhen2 and SIFT both predicted this amino acid
change to be damaging. A recent study found that rs2228467 is
significantly associated with lower circulating monocyte counts in
the blood (p = 1.5761027) [69]. If the rs2228467 polymorphism
affects the chemokine function of CCBP2 or CCL2, then this
could have downstream effects on the recruitment of macrophages
and dendritic cells and, in turn, monocyte development.
CCL2 is known to be a necessary component in monocytes
crossing the blood brain barrier [61,70]. Our findings suggest that
increased CCL2 associated with variation at rs2228467 may cause
a chemotactic response that results in lower levels of circulating
monocytes in the blood. While rs2228467 has strong effects on
CCL2 levels and CSF CCL2 levels change in Alzheimer’s disease,
this SNP does not appear to impact risk for AD or CSF Ab42
levels (p = 0.45) [9]. However, as CCL2 has been implicated in the
pathogenesis of diseases characterized by monocytic infiltrates, like
psoriasis [71], rheumatoid arthritis [72] and atherosclerosis [73]
further investigation of rs2228467 with regard to these and related
diseases is clearly warranted.
Here we have demonstrated in human subjects that SNPs in the
CCBP2 gene are significantly associated with elevated CSF CCL2
protein levels. While, CSF CCL2 protein levels are not signifi-
cantly associated with AD risk, evidence in mouse and cell models
of AD suggest that increasing CCL2 levels increases microgliosis,
amyloid plaque accumulation, and neuronal toxicity associated
with Ab. Taken together, these findings implicate CCBP2 and
CCL2 as risk factors for AD pathogenesis.
Chemokine (C-C motif) ligand 4 (CCL4)
The CCL4 protein is encoded by the CCL4 gene (17q12).
Studies evaluating the relationship between AD and inflammation
have shown that CCL4 is expressed in subpopulations of reactive
astrocytes and in microglia [74]. Neuritic plaques in AD are
surrounded by activated microglia and astrocytes, which may
produce inflammatory products when stimulated with Ab [75].
Macrophages showed an increased secretion of CCL4 when
treated with Ab. Current information concerning CCL4 and other
plaque-associated chemokines suggests that their production plays
a role in the recruitment and accumulation of astrocytes and
microglia in senile plaques [76]. These data suggest a possible
relationship between CCL4 and AD pathogenesis.
We identified association between several SNPs, including one
non-synonymous SNP, one synonymous SNP and five markers
with predicted regulatory effects, and CSF CCL4 levels. Condi-
tional analyses suggest that these SNPs tag a single association
signal in this region. These SNPs do not show association with AD
in the IGAP dataset or with CSF Ab42, Tau or pTau181 levels
(table 3). In addition, CSF CCL4 levels are not significantly
associated with ptau181/Ab42 ratio, a predictor of AD status [50].
These results do not indicate a role for CCL4 levels in risk for AD.
However, CCL4 may play a role in HIV Type 1 transmission,
AIDS disease progression, and acute kidney injury [77,78]. Thus it
will be important to evaluate the impact of rs6441977 (V168M
polymorphism in CCRL2; associated with decreased CCL4 levels)
and other markers with regulatory effects, on these and related
diseases.
Interleukin 6 receptor (IL6R)
The interleukin 6 receptor (IL6R) is a protein encoded by the
IL6R gene (1q21). Interleukin 6 is a potent pleiotropic pro-
inflammatory cytokine that regulates cell growth and differentia-
tion and plays an important role in the immune response and may
also play a role in hippocampal neurogenesis [79].
We identified association with sIL6R levels for several SNPs in the
IL6R region. Conditional analyses suggest that this is a single signal is
driven by rs61812598 and other SNPs in high LDwith these markers.
Among these, rs2228145, rs3811448 and rs4129267 have predicted
functional effects (see table 3). Rs3811448, a non-synonymous
marker in the associated region is not significant when conditioning
upon rs61812598, rs4129267 or rs2228145. Conversely, both
rs61812598 rs4129267 and rs2228145 remain highly significant
upon conditioning for rs3811448. This makes it clear that there is a
single signal in this region, tagged by rs61812598, rs4129267 and
rs2228145, which are in complete LD with each other.
Rs2228145 is a non-synonymous polymorphism in the IL6R
gene, (D358A). While both SIFT and Polyphen 2 predict this
change to be benign, rs2228145 has recently been shown to
significantly increase plasma concentrations of sIL-6R, and reduce
concentrations of membrane-bound IL-6R, resulting in impaired
IL-6 responsiveness [80]. These results demonstrate that conse-
quential changes in protein levels, likely resulting from the
rs2228145 polymorphism, may translate into a functional impair-
ment in IL-6R signaling. The rs2228145 polymorphism and other
SNPs in this region have previously been shown to be significantly
associated with plasma sIL-6 levels [21,81] Trans-signaling is
important for IL6-mediated cellular communication with molec-
ular targets and that blocking trans-signaling lessen the deleterious
effects of IL6 signaling [79]. Trans-signaling occurs via sIL6R,
which is the proteolyzed product of IL6R. IL6R is proteolyzed by
c-secretase, which also cleaves APP [82]. Thus, polymorphisms in
IL6R that modify IL6 signaling may result in modulation of
signaling to many downstream targets that directly or indirectly
influence AD pathogenesis.
Additionally, rs2228145 has been implicated previously as
significantly increasing the risk of sporadic AD in a Chinese Han
population in subjects without the APOE e4 allele [83]. While
sIL6R levels have been previously reported to decrease in AD
cases [84], a recent study using a much larger sample found a
significant increase in CSF sIL6R levels and increasing ptau181/
Ab42 ratio [50], suggesting a possible relationship between sIL6R
levels and AD pathogenesis.
It has been proposed that there is a reciprocal relationship
between IL-6 and Ab. The IL-6/sIL-6R complex is reported to
enhance APP transcription and expression [85–87]. Based on
these data, rs2228145, which is associated with increased sIL6R
levels, would be predicted to alter CSF Ab42 levels and risk for
AD. Unfortunately, we did not detect association of markers in
IL6R with AD risk in the IGAP analysis and association with AD
biomarkers was weak and inconsistent (table 3).
Rs4129267 is located within the intronic region of IL6R. This
SNP is inferred to be ‘‘likely to affect binding’’ of the Olf-1
transcription factor using RegulomeDB. Like rs2228145, this
marker is associated with sIL6R levels [21,81]. In addition, this
marker has been reported to be associated with levels of fibrinogen
and C-reactive protein in blood as well as asthma and pulmonary
function [31,32,88–90]. While it remains unclear what the causal
marker is for this association signal due to the high levels of LD,
the putative functional effects of both rs2228145 and rs4129267
make them top candidates for future investigation.
Dysregulated production of IL6 and its receptor are implicated
in the pathogenesis of many diseases, including multiple myeloma
[91], autoimmune diseases [92], and prostate cancer [93]. In
addition, the association of several significant SNPs in our study
with asthma, C-reactive protein levels and coronary heart disease
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highlights the relationship between the inflammatory response and
these disorders. This information suggests a central role for the
IL6/sIL6R complex in these and possibly other diseases and
suggests that further characterization of the effects of rs2228145
and rs4129267 on human disease phenotypes is warranted.
In conclusion, we have identified significantly associated SNPs
for five different AD-related analytes. These associations are
robust across different biological fluids, dementia status and
inferred presence of AD pathology both within and between
independent sample sets. The SNPs observed to be associated with
CSF ACE and MMP3 levels also appear to show association with
AD in the predicted direction, providing support for previous
hypotheses of involvement of these genes and their function in
amyloid clearance for risk for AD. While inflammation is known to
play an important role in AD, the pro-inflammatory markers
investigated here, and their associated SNPs, do not appear to
alter AD risk or disease progression. However, because the
immune system is an exceedingly complex set of signaling cascades
that must be perfectly regulated in order to function properly and
because this regulation involves constant flux, we may not be able
to fully capture the subtle effects in the function of these proteins
that have a cumulative effect on AD pathogenesis over the course
of a lifetime. The reproducibility of our findings in cognitively
normal individuals and in plasma levels of the respective proteins
as well as putative functional effects of these variants suggest that
these SNPs may directly affect their respective proteins. Thus,
insights into the genetic basis of variance in important pro-
inflammatory protein levels are relevant to other diseases that are
modulated by those processes. Finally, our findings demonstrate
the continued utility of an endophenotype-based approach to
finding functional alleles and disease-associated loci.
Methods
Subjects
ADNI. Data used in the preparation of this article were
obtained from the ADNI database (www.loni.ucla.edu\ADNI).
CSF was collected as described previously [94]. Genetic and
phenotypic data for 308 samples was available for this study.
Demographics of the samples included in this manuscript are
reported in Table 5.
Knight ADRC. CSF samples from 266 individuals from the
Knight-Alzheimer’s disease Research Center at Washington
University School of Medicine (Knight ADRC) were used in this
study. A detailed description of these samples and CSF collection
methods has been published previously [9,95]. Demographics of
these samples are described in Table 5.
Phenotypes
CSF and plasma samples from the Knight ADRC were
evaluated for levels of 190 analytes using the Human Discover-
yMAP Panel and a Luminex 100 platform. CSF and plasma
samples from the ADNI sample were assessed using the same
Human DiscoveryMAP Panel and measurement platform [21,94].
After filtering each set independently for phenotypes that had valid
measurements in at least 90% of the samples, the intersection
resulted in 76 analytes. For each of the 76 analytes that passed
quality assurance in both datasets we performed a PubMed search
on August 11, 2013. The purpose of this literature search was to
reduce the phenotype list to those that are relevant to our AD
centered samples from the Knight ADRC and ADNI, thus
reducing the dimensionality of the data and concentrating
statistical power on the most relevant phenotypes. Search terms
included any of the following three terms, the name of the analyte
on the chip, the official gene name and the official protein name
and the term ‘‘Alzheimer’s disease’’. Analytes with more than 50
search results are considered to be ‘‘AD-related’’. For analytes
with fewer than 50 search results we inspected the manuscripts
manually to determine whether there was evidence for a
relationship with AD. A list of all analyte names on the chip
along with official gene and protein names and results of the
literature search is provided in supplementary Table S5.
Genotyping
All samples were genotyped using the Illumina 610 or the
Omniexpress chip. Prior to statistical analysis, sample data were
Table 5. Sample characteristics.
Knight ADRC ADNI
N 266 308
Percent Female 60% 40%
Percent APOE e4 positive 33% 48%
Percent CDR =0 35% 21%
Percent Amyloid positive* 45% 52%
Percent CDR =0 and amyloid positive 36% 37%
Percent CDR.= 0.5 and amyloid positive 72% 84%
Mean CSF ACE Levels ng/ml (SD) 3.26 (1.23) 0.306 (0.16)**
Mean CSF CCL2 Levels pg/ml (SD) 682 (183) 2.72 (0.13)**
Mean CCL4 Levels pg/ml (SD) 17.7 (7.14) 1.22 (0.20)**
Mean CSF IL6R Levels ng/ml (SD) 1.13 (0.34) 0.001 (0.15)**
Mean CSF MMP3 Levels ng/ml (SD) 0.10 (0.065) 20.47 (0.20)**
For samples from the Knight Alzheimer’s Disease Research Center and Alzheimer’s Disease Neuroimaging Initiative the number of samples, percent female, percent of
APOE e4 carriers, percent of non-demented (CDR= 0) samples, percent amyloid positive, percent of CDR= 0 samples that are amyloid positive, percent of CDR.=0.5
samples that were amyloid positive) and mean and standard deviation of the key analytes from this study are shown.
*Amyloid positivity is inferred from CSF AB42 levels (KADRC AB42,500 pg/ml; ADNI AB42,192 pg/ml).
**ADNI phenotypes were obtained from ADNI after transformation to approximate a normal distribution.
doi:10.1371/journal.pgen.1004758.t005
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filtered using rigid quality control (QC) criteria by array: minimum
call rate (98%), minimum minor allele frequency (2%), and
exclusion of SNPs out of Hardy-Weinberg equilibrium (p,
161026). Unanticipated duplicates and related individuals were
prioritized after calculating pairwise genome-wide estimates of
identity-by-descent. Eigensoft was used to calculate principal
component factors for each sample and confirm ethnicity [96].
These calculations were included as covariates in our analysis to
adjust for possible confounding effects of population stratification.
Imputation
The 1000 genome data (June 2012 release) and the Beagle
software were used to impute genotypes in the combined ADNI
and Knight ADRC samples [97]. SNPs with a Beagle r2 of 0.3 or
lower, a minor allele frequency (MAF) lower than 0.05, out of
Hardy-Weinberg equilibrium (p,161026), a call rate lower than
95% or a Gprobs score lower than 0.90 were removed. A total of
5,815,690 SNPs passed the QC process.
Statistical analysis
The Kolmogorov-Smirnov goodness-of-fit test was performed to
evaluate normality of the 59 phenotypes of interest in the Knight
ADRC samples. When deviations were observed, phenotypes were
log transformed to approximate a normal distribution. The ADNI
data for these samples and phenotypes had already been adjusted
to fit normal distribution patterns by the ADNI biomarker core.
Associations reported for age and gender were performed in
cognitively normal samples only to reduce potential confounds of
dementia.
We performed a genome-wide association for each of the 59
phenotypes to identify genetic loci associated with protein levels in
CSF. For the initial association analysis in each series we used
PLINK to perform linear regression and evaluated the association
between the additive model for 5.8M SNPs and each phenotype
[98]. Age, gender, and the principal components from Eigensoft
analysis were included as covariates. Variance explained by each
marker is reported as the difference in the model r2 between full
models with and without the SNP included as a variable.
Association of SNPs of interest with plasma analyte levels in the
ADNI and Knight ADRC samples was calculated using the same
approach. Analysis of each sample separately reduces the possible
confound of demographic or ascertainment differences between
the ADNI and Knight ADRC samples.
Genome-wide association results from the two datasets were
meta-analyzed using the default settings in METAL [99].
Genomic inflation factor scores (GIF) were estimated using the
R package GenABEL [100]. We set a strict and extremely
conservative study-wide alpha level of 1.46610210 for the
combined analysis. This was calculated by applying a Bonferroni
correction for 5.8 million SNPs and 59 analytes, or 342.2 million
tests. SNPs that met the initial significance criteria were further
filtered using the following criteria. First, we rejected SNPs where
the direction of the effect was different in the Knight ADRC and
ADNI datasets. Second, we removed all SNPs where the minor
allele frequency was less than 5% (unless they were directly
genotyped). Finally, we rejected all associations with phenotypes
where the genomic inflation factor was greater than 1.03 (GIF was
calculated without SNPs where MAF is ,0.05). Conditional
analyses on each of the genome-wide significant SNPs were
conducted using the –condition function in PLINK. We also
performed additional analyses in the genome-wide significant loci
to determine the stability of the results when stratified by clinical
AD status and by CSF AB42 levels. CSF AB42 strata were based
on levels that approximate amyloid deposition detected in PET
scans using Pittsburgh Compound B (PIB). For the KADRC
samples values less than 500 pg/ml indicate PIB retention/Ab
deposition, while values greater than 500 pg/ml indicate PIB
negativity and the absence of Ab deposition [95]. For the ADNI
samples values less than 192 pg/ml indicate retention/Ab
deposition, while values greater than 192 pg/ml indicate PIB
negativity and the absence of Ab deposition [101].
We used the R package Multiphen, which performs a multivar-
iate test of the linear combination of phenotypes most associated
with the genotypes at each SNP, to evaluate each of the top hits for
joint effects on multiple phenotypes in the study [37]. Analysis was
carried out in the KADRC and ADNI samples separately using
default settings as described here (http://cran.at.r-project.org/
web/packages/MultiPhen/vignettes/MultiPhen.pdf).
GIF statistic for IL6R
Initial results of IL6R indicated a GIF statistic greater than 1.03
suggesting the p-values were inflated by confounding variables. By
removing a 500 kb window on either side of the strongest signal
we identified that the inflation was due to the large number of
highly significant p-values surrounding the IL6R gene (adjusted
GIF=1.017). We did not remove this phenotype as it appears the
inflation is due to a strong and replicable association signal in this
single region. We analyzed other phenotypes that failed GIF
quality control using the same strategy and did not observe similar
phenomena.
Association with risk for Alzheimer’s disease
For each locus where association was detected with the CSF
endophenotypes we obtained data from the International
Genomics of Alzheimer’s Project (IGAP) association study of AD
Stage 1 results [30]. IGAP is a large two-stage study based upon
genome-wide association studies (GWAS) in individuals of
European ancestry. In stage 1, IGAP used genotyped and imputed
data for 7,055,881 single nucleotide polymorphisms (SNPs) to
meta-analyse four previously-published GWAS datasets consisting
of 17,008 Alzheimer’s disease cases and 37,154 controls (The
European Alzheimer’s disease Initiative – EADI the Alzheimer
Disease Genetics Consortium – ADGC The Cohorts for Heart
and Aging Research in Genomic Epidemiology consortium –
CHARGE The Genetic and Environmental Risk in AD consor-
tium – GERAD). In stage 2, 11,632 SNPs were genotyped and
tested for association in an independent set of 8,572 Alzheimer’s
disease cases and 11,312 controls. Finally, a meta-analysis was
performed combining results from stages 1 & 2.
Bioinformatics analyses
We used ANNOVAR to annotate SNPs of interest with location
and functional information [102]. RegulomeDBwas used to annotate
SNPs within known and predicted regulatory elements [103].
We used SIFT and POLYPHEN2 for preliminary assessments
of the functional consequences of amino acid changes [104,105].
All data collection was conducted under approval by the
appropriate Institutional Review Boards. Analyses presented here
were approved by the Institutional Review Board at Brigham
Young University (E110252).
Supporting Information
Figure S1 Manhattan plots for ACE. The x-axis shows each
marker that was analyzed, sorted by chromosome and position.
The y-axis shows the 2log10 of the p-value for association with the
respective phenotype.
(PDF)
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Figure S2 Manhattan plots for CCL2. The x-axis shows each
marker that was analyzed, sorted by chromosome and position.
The y-axis shows the 2log10 of the p-value for association with the
respective phenotype.
(PDF)
Figure S3 Manhattan plots for CCL4. The x-axis shows each
marker that was analyzed, sorted by chromosome and position.
The y-axis shows the 2log10 of the p-value for association with the
respective phenotype.
(PDF)
Figure S4 Manhattan plots for IL6R. The x-axis shows each
marker that was analyzed, sorted by chromosome and position.
The y-axis shows the 2log10 of the p-value for association with the
respective phenotype.
(PDF)
Figure S5 Manhattan plots for MMP3. The x-axis shows each
marker that was analyzed, sorted by chromosome and position.
The y-axis shows the 2log10 of the p-value for association with the
respective phenotype.
(PDF)
Table S1 All study-wide significant variants. For each marker
the chromosome (CHR), base pair position (BP), Alleles (Allele1,
Allele2), p-value from the ADNI dataset (ADNI), p-value from the
Knight ADRC dataset (Knight ADRC), combined sample p-value
(Combined), direction of association (Direction), minor allele
frequency (MAF), Genotyping status, function, Nearest Genes,
exonic function, amino acid change and regulome score is
provided.
(XLSX)
Table S2 Association of CSF ACE, IL6R, CCL4, MMP3 and
CCL2 levels with age and gender. The slope and p-value for linear
regression with age and gender is shown for the ADNI and
KADRC samples. P-values of less than 0.05 are shown in bold.
(XLSX)
Table S3 Association of plasma ACE, IL6R, CCL4, MMP3 and
CCL2 levels with age and gender. The slope and p-value for linear
regression with age and gender is shown for the ADNI and
KADRC samples. P-values of less than 0.05 are shown in bold.
(XLSX)
Table S4 Multiphen results. For each SNP and phenotype the p-
value from ADNI, Knight ADRC, metaanalysis results are shown.
(XLSX)
Table S5 Analyte names. The name of each analyte in the
Human Discovery MAP documentation, official protein name and
official structural gene name and resuls of the PubMed search for
previous links to Alzheimer’s disease are presented.
(XLSX)
Text S1 Descriptions of each gene.
(DOCX)
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